INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA-RELATED CYSTOID MACULAR EDEMA
| Autor: | Roberto Gallego-Pinazo, Hernando Zegarra, Luiz H. Lima, Raphael Moura, J. Fernando Arevalo, Robert E. Foster, Esat Cinar, Shree K. Kurup, Ozcan Kayikcioglu, Robert A. Sisk, Alan Kimura, Anderson Teixeira, Riad A. Bejjani, Huda Sheheitli, Ethem Tansu Erakgün, Igor Kozak, Rola N. Hamam, Laila Al-Shaar, Ahmad M. Mansour, Mauricio Maia, Cem Küçükerdönmez, Marilita M Moschos |
|---|---|
| Přispěvatelé: | Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon, Department of Ophthalmology, American University of Beirut, Beirut, 113-6044, Lebanon, Department of Ophthalmology, Izmir University, Faculty of Medicine, Izmir, Turkey, Department of Ophthalmology, Cincinnati Eye Institute, University of Cincinnati, Cincinnati, OH, United States, Department of Ophthalmology, Universidade Federal de São Paulo, São Paulo, Brazil, Department of Ophthalmology, University of Athens, Athens, Greece, Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil, Vascular Medicine Program, American University of Beirut Medical Center, Beirut, Lebanon, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States, Department of Ophthalmology, Celal Bayar University, Manisa, Turkey, Division of Vitreoretinal Diseases and Surgery, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, Department of Ophthalmology, Wake Forest University, Winston Salem, NC, United States, Retina Associates of Cleveland, Beachwood, OH, United States, Department of Ophthalmology, University and Polytechnic Hospital la Fe, Valencia, Spain, Department of Ophthalmology, Hotel Dieu de France, Beirut, Lebanon, Department of Ophthalmology, Ekol Eye Hospital, Izmir, Turkey, Department of Ophthalmology, University of Colorado, Aurora, CO, United States, School of Medicine, Catholic University Brasilia, Brasilia, Brazil |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Intraocular pressure Visual acuity Time Factors genetic structures Visual Acuity Dexamethasone 0302 clinical medicine dexamethasone implant Macula Lutea Drug Implants General Medicine Middle Aged Treatment Outcome Intravitreal Injections Female medicine.symptom Retinitis Pigmentosa Tomography Optical Coherence medicine.drug Adult medicine.medical_specialty Adolescent Macular Edema 03 medical and health sciences Young Adult Cataracts retinitis pigmentosa Ophthalmology Retinitis pigmentosa medicine Humans In patient Macular edema Glucocorticoids Retrospective Studies Dose-Response Relationship Drug business.industry medicine.disease eye diseases Surgery 030104 developmental biology 030221 ophthalmology & optometry sense organs Implant business cystoid macular edema intraocular pressure Follow-Up Studies |
| Zdroj: | RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 1539-2864 0275-004X |
| Popis: | Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (m) decreased from 506 ± 288 m to 311.7 ± 71.6 m (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage. © Ophthalmic Communications Society, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|